Embecta (NASDAQ:EMBC – Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.700-2.900 for the period, compared to the consensus earnings per share estimate of 2.270. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.
Embecta Price Performance
NASDAQ EMBC opened at $14.41 on Tuesday. The stock’s 50 day simple moving average is $14.33 and its 200-day simple moving average is $14.04. The company has a market cap of $831.46 million, a PE ratio of 12.01 and a beta of 0.97. Embecta has a 1-year low of $9.93 and a 1-year high of $19.79.
Embecta Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 18th. Shareholders of record on Friday, December 6th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 4.16%. Embecta’s payout ratio is currently 50.00%.
About Embecta
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
See Also
- Five stocks we like better than Embecta
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Stocks That Authorized $1 Billion Stock Buybacks to Boost Value
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Pure Storage’s GenAI Pods and AI Trends Could Spark Recovery
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Is Seaboard Corporation a Thanksgiving Feast for Investors?
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
